1. Home
  2. WIW vs CTNM Comparison

WIW vs CTNM Comparison

Compare WIW & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Inflation-Linked Opportunities & Income Fund

WIW

Western Asset Inflation-Linked Opportunities & Income Fund

SELL

Current Price

$7.93

Market Cap

505.4M

Sector

Finance

ML Signal

SELL

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$8.14

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIW
CTNM
Founded
2004
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
505.4M
550.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
WIW
CTNM
Price
$7.93
$8.14
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $22.14
AVG Volume (30 Days)
332.3K
★ 1.3M
Earning Date
01-01-0001
11-06-2026
Dividend Yield
★ 11.14%
N/A
EPS Growth
N/A
★ 0.46
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$7.83
$6.73
52 Week High
$8.95
$17.79

Technical Indicators

Market Signals
Indicator
WIW
CTNM
Relative Strength Index (RSI) 43.66 32.94
Support Level $7.84 $6.73
Resistance Level $8.00 $13.72
Average True Range (ATR) 0.06 0.97
MACD 0.02 -0.05
Stochastic Oscillator 50.56 20.06

Price Performance

Historical Comparison
WIW
CTNM

About WIW Western Asset Inflation-Linked Opportunities & Income Fund

Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: